ANRO beat EPS expectations by 15.54%
Mar 21, 2025, 10:34 PM
0.00%
What does ANRO do
Alto Neuroscience, a clinical-stage biopharmaceutical company based in Los Altos, California, focuses on developing psychiatric drugs using its Precision Psychiatry Platform. The company has five clinical-stage assets targeting depression and schizophrenia, with an IPO on February 2, 2024.
Alto Neuroscience (ANRO) reported a positive EPS surprise in its most recent quarterly earnings. For the most recent quarter, Alto Neuroscience's actual EPS was -$0.56, beating the estimate of -$0.66 per share, resulting in a 15.54% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.